Scancell (SCLP) Competitors

Scancell logo
GBX 80 +0.20 (+0.25%)
As of 04:13 AM Eastern

SCLP vs. HZD, PRTC, AVCT, ARIX, and CIR

Should you buy Scancell stock or one of its competitors? Scancell's main competitors and comparable companies include Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Avacta Group (AVCT), Arix Bioscience (ARIX), and Circassia Group (CIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

1.3% of Scancell shares are owned by institutional investors. 13.2% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company Overall Sentiment
Horizon Discovery Group plc (HZD.L) Neutral
Scancell Neutral

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A
ScancellN/AN/A-£6.75M-£17.30N/A

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Horizon Discovery Group plc (HZD.L)N/A N/A N/A
Scancell -116.98%128.87%-45.28%

Summary

Horizon Discovery Group plc (HZD.L) and Scancell tied by winning 4 of the 8 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

1.3% of Scancell shares are held by institutional investors. Comparatively, 31.4% of PureTech Health shares are held by institutional investors. 13.2% of Scancell shares are held by insiders. Comparatively, 13.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PureTech Health has a net margin of 7.53% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 128.87% -45.28%
PureTech Health 7.53%0.14%-13.39%

Scancell has higher earnings, but lower revenue than PureTech Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£17.30N/A
PureTech Health£6.37M45.99-£91.86MN/AN/A

PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 325.46%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Scancell has a beta of 0.689, suggesting that its share price is 31% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, PureTech Health had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Scancell. PureTech Health's average media sentiment score of 0.75 beat Scancell's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company Overall Sentiment
Scancell Neutral
PureTech Health Positive

Summary

PureTech Health beats Scancell on 12 of the 14 factors compared between the two stocks.

How does Scancell compare to Avacta Group?

Scancell (LON:SCLP) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Scancell. Scancell's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company Overall Sentiment
Scancell Neutral
Avacta Group Neutral

Scancell has a beta of 0.689, indicating that its share price is 31% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -35,730.97%. Scancell's return on equity of 128.87% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 128.87% -45.28%
Avacta Group -35,730.97%-1,293.07%-21.80%

1.3% of Scancell shares are held by institutional investors. Comparatively, 2.9% of Avacta Group shares are held by institutional investors. 13.2% of Scancell shares are held by insiders. Comparatively, 49.1% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Scancell has higher earnings, but lower revenue than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Scancell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£17.30N/A
Avacta Group£113K2,207.68-£30.08M-£9.24N/A

Summary

Avacta Group beats Scancell on 7 of the 11 factors compared between the two stocks.

How does Scancell compare to Arix Bioscience?

Scancell (LON:SCLP) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, Scancell's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Scancell Neutral
Arix Bioscience Neutral

Arix Bioscience has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£17.30N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

Scancell has a beta of 0.689, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

1.3% of Scancell shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 13.2% of Scancell shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arix Bioscience has a net margin of 105.64% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat Arix Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 128.87% -45.28%
Arix Bioscience 105.64%6.41%2.18%

Summary

Arix Bioscience beats Scancell on 9 of the 10 factors compared between the two stocks.

How does Scancell compare to Circassia Group?

Circassia Group (LON:CIR) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Circassia Group has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 128.87% beat Circassia Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Scancell -116.98%128.87%-45.28%

1.3% of Scancell shares are held by institutional investors. 13.2% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Circassia Group has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
ScancellN/AN/A-£6.75M-£17.30N/A

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Scancell Neutral

Summary

Circassia Group beats Scancell on 5 of the 8 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLP vs. The Competition

MetricScancellBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£108.53M£4.06B£7.83B£2.78B
Dividend YieldN/A3.63%2.47%5.11%
P/E Ratio-4.6227.9434.0023.20
Price / SalesN/A15.778.485.01
Price / Cash7.8622.9521.0120.23
Price / Book-205.244.184.462.48
Net Income-£6.75M-£24.15M£3.52B£5.88B
7 Day PerformanceN/A-7.81%-5.94%-1.55%
1 Month Performance-13.98%-6.00%-4.59%-2.96%
1 Year Performance-17.99%-8.10%-1.93%7.77%

Scancell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLP
Scancell
N/AGBX 80
+0.3%
N/A-20.0%£108.53MN/AN/A51
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63MN/A416
PRTC
PureTech Health
1.9198 of 5 stars
GBX 123.04
-0.8%
GBX 508
+312.9%
-3.3%£301.68M£6.37MN/A300
AVCT
Avacta Group
N/AGBX 59
-4.2%
N/A-29.6%£258.20M£113KN/A120
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919

Related Companies and Tools


This page (LON:SCLP) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners